LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study - Concepedia

Concepedia

Publication | Open Access

LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study

DOI Full Paper Access

16

Citations

0

References

2025

Year

Christof Vulsteke, H. Kaimakliotis, Pongwut Danchaivijitr, Maksim Sabadash, Alejo Rodríguez‐Vida, Zuo‐Feng Zhang, V. Atduev, Yunus Emre GÖĞER, Steffen Rausch, Su Hwan Kang,

Annals of Oncology

No additional data available for this publication yet. Check back later!